Topics

Early Conversion of Dasatinib in CML-CP Patients

2019-10-28 13:57:11 | BioPortfolio

Summary

Chronic myeloid leukemia (CML) is a malignant disease of acquired hematopoietic stem cells. The BCR-ABL fusion gene is the pathogenic basis of CML. Tyrosine kinase inhibitors (TKIs) are targeted drugs for this fusion protein. With the wide clinical application of TKIs, the efficacy of CML patients has been greatly improved. However, there are still a significant number of patients who have poor response to the first generation of TKI drugs, imatinib, most of them have early molecular response failures (BCR-ABL(IS)>10% at 3 or 6 months) ,which means lower rates of molecular response, increased risk of progression, and higher overall survival. For them, the early conversion of dasatinib might be a better choice.

Study Design

Conditions

Validity and Safety

Intervention

Dasatinib 100 MG

Location

NanfangH
Guangzhou
Guangdong
China
510515

Status

Enrolling by invitation

Source

Nanfang Hospital of Southern Medical University

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-28T13:57:11-0400

Clinical Trials [350 Associated Clinical Trials listed on BioPortfolio]

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.

Study of Dasatinib(BMS-354825) in Patients With Solid Tumors

The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose(MAD) of Dasatinib (BMS-354825) in patients in Japan.

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

The purpose of this study is to explore the efficacy and safety of dasatinib 70 mg once daily as first line therapy in patients with early chronic phase (CP) chronic myeloid leukemia (CML)...

Korean Early Access Program

This protocol allows CML and Ph+ ALL subjects who are resistant to or intolerant of imatinib mesylate, to potentially benefit from dasatinib. It is intended to provide patients with acces...

Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL

The goal of this clinical research study is to find out if intensive chemotherapy combined with dasatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome a...

PubMed Articles [6108 Associated PubMed Articles listed on BioPortfolio]

Conjugation Of Dasatinib With MHI-148 Has A Significant Advan-tageous Effect In Viability Assays For Glioblastoma Cells.

We hypothesized conjugation of the near-IR dye MHI-148 to dasatinib might produce a potential theranostic for glioblastoma. In fact, the conjugate bound the kinases Src and Lyn, and inhibits the viabi...

Responses to Dasatinib as a Second- and Third-Line Tyrosine Kinase Inhibitor in Chronic Phase Chronic Myeloid Leukaemia Patients.

We retrospectively evaluated the efficacy and safety of dasatinib among 48 Chinese patients with chronic phase chronic myeloid leukaemia. The proportions of patients achieving the optimal molecular re...

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.

Dasatinib, a potent Bcr-Abl tyrosine kinase inhibitor, is approved for the treatment of chronic-phase chronic myeloid leukemia (CML-CP) in the frontline and salvage settings. Notable side effects incl...

Dasatinib Ameliorates Chronic Pancreatitis Induced by Caerulein via Anti-fibrotic and Anti-inflammatory Mechanism.

Chronic pancreatitis (CP) is characterized by persistent inflammation and fibrosis of the pancreas. To date, no clinical therapy is available to reverse the inflammatory damage or pancreatic fibrosis...

A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.

Src signaling is markedly upregulated in patients with invasive glioblastoma (GBM) after the administration of bevacizumab. The Src family kinase inhibitor dasatinib has been found to effectively bloc...

Medical and Biotech [MESH] Definitions

Freedom from exposure to danger and protection from the occurrence or risk of injury or loss. It suggests optimal precautions in the workplace, on the street, in the home, etc., and includes personal safety as well as the safety of property.

Activities involved in ensuring the safety of FOOD including avoidance of bacterial and other contamination.

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

An office in the Department of Labor responsible for developing and establishing occupational safety and health standards.

An institute of the CENTERS FOR DISEASE CONTROL AND PREVENTION which is responsible for assuring safe and healthful working conditions and for developing standards of safety and health. Research activities are carried out pertinent to these goals.

More From BioPortfolio on "Early Conversion of Dasatinib in CML-CP Patients"

Quick Search

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...


Searches Linking to this Trial